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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a major public health problem for both 
industrialised and developing countries (Viegi et al., 2001). The prevalence of COPD is 
increasing worldwide, resulting in a substantial economic burden, including direct and 
indirect health-care costs (Chapman et al., 2006). 
Non-adherence in COPD is common and poses a significant barrier to optimal disease 
management. According to the World Health Organization (WHO), adherence to long-term 
therapies averages only 50% (WHO, 2003). Patient adherence in chronic diseases can result 
in poor health outcomes and increased health-care expenditures (WHO, 2003). 
Discontinuation of COPD therapy contributes to increasing the frequency of exacerbations, 
the number of hospitalisations and the mortality rate (Bourbeau & Bartlett, 2008; Regueiro et 
al., 1998; Vestbo et al., 2011). 
Clinical trials may overestimate the level of adherence to medication regimens. Adherence 
rates in clinical trials have been expected to be approximately 70%–90% among patients 
with COPD (Kesten et al., 2000; van Grunsven et al., 2000; Rand et al., 1995). In clinical 
practice, these rates are only in the range of 20%–60% (Agh et al., 2011; Bosley et al., 1994; 
Dolce et al., 1991; Krigsman et al., 2007a). This difference reflects the fact that patient 
adherence may be an important explanatory factor of the difference between the efficacy of 
treatment under experimental conditions and the real-world effectiveness of the treatment 
(Revicki & Frank, 1999). 
Non-adherence in patients with COPD has a number of causes, including factors related to 
the characteristics of the patient, the disease, the therapies and the health-care provider–
patient relationship (Baiardini et al., 2009; Restrepo et al., 2008; WHO, 2003). Physicians 
should understand the factors and the strategies that facilitate adherence to improve the 
effectiveness of the therapy. 
The goals of this chapter are as follows: to highlight the importance of adherence in the 
management of COPD; to introduce the reader to the concepts of adherence, compliance 
and persistence; to address different methods of measuring adherence; to identify factors 
related to adherence; and to emphasise strategies to enhance adherence in patients with 
COPD. 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
276 
2. General overview of adherence 
There are a number of terms used to describe the extent to which a patient undertakes the 
recommendations (medication regimens, lifestyle changes, etc.) of health-care providers. 
The most commonly used terms are compliance, adherence and persistence. 
2.1 Terminology: Compliance, adherence and persistence 
The definitions used to describe the concepts of compliance, adherence and persistence are 
not standardised, which causes many difficulties when comparing or combining results of 
different studies. The definitions from the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and the WHO are the most widely accepted in the literature. 
Medication compliance, as defined by the ISPOR, “refers to the act of conforming to the 
recommendations made by the provider with respect of timing, dosage and frequency of 
medication taking” (Carmer et al., 2008). Compliance is expressed as an index number, 
which is typically given as a percentage and refers to a specified time interval. One of the 
most commonly used models for calculating medication compliance is the medication 
possession ratio (MPR). In the model of the MPR, the number of days of medication 
supplied within the refill interval is divided by the number of days in the refill interval 
(Peterson et al., 2007). Medication compliance may also be reported as a dichotomous 
variable, classifying patients into good and poor (or non-) compliance categories (Table 1). 
The cut-off point of compliance should be determined according to medication and type of 
disease. However, it is generally set independently at 80%, whether this compliance rate is 
adequate for disease control or not (Carmer et al., 2008).  
 
Drugs Months 
( 1 month = 30 days) 
Supply 
(days) 
MPR 
A x x x x x x    x x x 9x30=270 270/360=0.75 
B  x x x x  x x x x   8x30=240 240/360=0.66 
C   x  x  x x  x x x 7x30=210 210/360=0.58 
∑ MPR: ((270+240+210)/3)/360 = 0.66 ń 66%* 
*:Patient is non-compliant (cut-off point: 80%). 
│x│: medication supplied,││: medication not supplied 
Table 1. Calculation of medication compliance: medication possession ratio (MPR) 
According to the definition of ISPOR, medication persistence may be described as “the 
duration of time from initiation to discontinuation of therapy” (Carmer et al., 2008). 
Persistence analyses must also define a permissible gap period, which specifies the 
maximum allowable time period between refills without discontinuation of the therapy. 
Persistence may be counted in days. However, it can also be given as the percentage of the 
number of persistent patients at the end of a predefined time period (Patricia et al., 2006) 
(Table 2). A patient’s drug taking behaviour can best be quantified using both parameters: 
medication compliance and persistence (Carmer et al., 2008). 
Although most research in the field has focused on medication compliance and persistence, 
therapeutic adherence certainly includes other non-drug therapeutic recommendations  
www.intechopen.com
 
Adherence to Therapy in Chronic Obstructive Pulmonary Disease 
 
277 
Patients Months 
(1 month = 30 days) 
Days
persistent 
(gap: 30 days)*
Persisted 180 
days** 
A x x x x   x x x    120 no 
B x x x x x x    x  x 180 yes 
C x x    x x   x  x 60 no 
*: Patients persisted an average of 120 days ((120+180+60)/3) 
**: 33% (1/3) of the patients were persistent for 180 days 
│x│: medication supplied,││: medication not supplied 
Table 2. Calculation of medication persistence 
(following diets, executing lifestyle changes, etc.) as well. Explanation of adherence by the 
WHO also reflects this concept. The WHO definition of adherence is the following: “the 
extent to which a person’s behaviour—taking medication, following a diet, and/or 
executing lifestyle changes—corresponds with agreed recommendations from a health-care 
provider” (WHO, 2003). This definition accurately highlights the importance of the patient’s 
active role in their own health-care, which emphasises that the relationship between the 
patient and the health-care provider should be based on a partnership, instead of a one-
sided paternal relationship.  
Recently, medication adherence has become the preferred term instead of medication 
compliance. The primary difference between compliance and adherence is that compliance 
reflects the patient as a passive recipient of medical advice. Furthermore, compliance has 
also been viewed as a judgmental term when applied to patient behaviour. Thus, 
medication adherence will be the preferred term from this point forward. 
2.2 Methods of measuring adherence 
Most studies in adherence research have focused on medication-taking behaviour. 
Therefore, the following is a brief overview of the methodology of the assessment of 
medication adherence in COPD. There are a number of ways to assess adherence; 
nevertheless, there is not a gold standard because each method has strengths and limitations 
(Table 3). 
The easiest way to assess medication adherence within clinical settings is to collect 
information from the patient themselves through questionnaires or patient diaries (Agh et 
al., 2011; Dolce et al., 1991; George et al., 2005, 2006a; Laforest et al., 2010). However, it 
should be mentioned that self-reporting methods may overestimate a patient’s drug-taking 
behaviour (Dompleing et al., 1992; Rand et al., 1992, 1995). Using postal administration can 
help to obtain data that are more objective because patients are normally intimidated by 
their health-care providers and tend to give them the expected answers (Agh et al., 2011). 
Another commonly used method is the analysis of electronic pharmacy records (Breekveldt-
Postma et al., 2007; Cramre et al., 2007; Jung et al., 2009). Retrospective database analysis is 
rapid and inexpensive. Nevertheless, this approach may also be inaccurate. It evaluates the 
prescriptions written by physicians or the prescriptions filled by patients, but not the 
medication intake directly.  
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 Advantage Disadvantage 
Indirect methods   
Patient self-report: adherence 
questionnaire, patient diary 
 
Easy to obtain Unreliable 
Pharmacy refill data Rapid 
Inexpensive 
Inaccurate:  
 Pharmacy database can be 
incomplete 
 No indication of ingestion 
Pill count, inhaler weighing Easy to obtain 
Inexpensive 
Inaccurate: 
 No indication of ingestion 
 “Dumping”* 
Electronic adherence 
monitoring 
Accurate measure of 
dosing history 
Expensive 
No indication of ingestion 
Therapeutic outcome Easy to obtain Clinical outcomes can depend 
on other factors  
Direct methods   
Direct observation of the 
medication intake 
Accurate indication of 
the ingestion 
Unpleasant for the patient 
Require large human resources 
Biological assay Confirm drug use Expensive 
Unpleasant for the patient 
Limited information regarding 
use over time 
Insensitive to inhaled drugs 
*”Dumping”: removing most of the medication at one time. 
Table 3. Methods of measuring adherence 
Pill count (Dompleing et al., 1992; van Grunsven et al., 2000) and canister weighing (Rand et 
al., 1995; Simmons et al., 2000) are widely used methods of adherence assessment in clinical 
trials. Pill counts are limited to oral medications, but canister weighing can also be used to 
monitor inhaled drugs. These approaches assess only the quantity of the medication 
removed from the canister without indication of ingestion, dose or dose frequency. 
Electronic compliance monitoring devices can provide more objective information about 
medication use than the aforementioned methods (Corden et al., 1997; Simmons et al., 1996, 
2000). The cap of the pill bottles can be equipped with a microchip that stores data about 
each opening. Electronic recording devices (chronologs) can be fitted to metered-dose 
inhalers and nebulisers as well. Electronic monitors provide an accurate measure of dosing 
history but also cannot confirm ingestion. The major disadvantage of this method is the 
price; it is relatively costly.  
Medication compliance can also be estimated based on direct assessments, such as direct 
observation of the medication intake or evaluation of blood levels or urinary excretion of the 
drug or its metabolite or drug-marker (Clark et al., 1996; Hatton et al., 1996). These methods 
are unpleasant for the patient and expensive. Interestingly, therapeutic drug monitoring 
may overestimate the actual adherence rate because patients tend to comply shortly before 
the drug test but not during the whole observation period. Another limitation is that a 
biochemical drug test is insensitive to inhaled medication. 
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The assessment of therapeutic adherence seems to be more complicated. However, clinical 
outcomes can be used to evaluate adherence, as these depend largely on the extent to which 
a patient undertakes the recommendations of health-care providers. 
3. Adherence with COPD therapy 
3.1 Adherence to medication 
Medication non-adherence can take many forms: failure to fill prescriptions (primary non-
adherence) or overuse, underuse or alteration of schedule or doses of medication (secondary 
non-adherence) (Bourbeau et al., 2007; George et al., 2007; Rand et al., 2005).  
Only a limited number of studies have evaluated adherence in patients with COPD. Jung et 
al. (Jung et al., 2009) examined medication adherence and persistence among a sample of 
COPD patients during their last year of life. The study reviewed the use of inhaled 
corticosteroids (ICS), long-acting β2 agonists (LABA), anticholinergics (AC) and 
methylxanthines (MTX), alone and in combination. The overall MPR to COPD medication 
was 44%. Approximately 30% of the patients persisted with the therapy, and the overall 
time to discontinuation was 94.2 days. These rates of cooperation are much lower than the 
drug-taking rates in other chronic diseases. Adherence in hypertension, dyslipidaemia and 
diabetes is, on average, 72% (MPR), and persistence is 63% (Cramer et al., 2008). In the 
previously mentioned study, Jung et al. (Jung et al., 2009) found differences between the 
mean MPRs of COPD drug classes (MTX: 52%, AC: 38%, ICS: 35%, LABA: 34%). Medication 
adherence was the highest with MTX. One possible explanation of this finding could be that 
elderly patients may have more difficulty using inhaled medications; therefore, they prefer 
oral drugs.  
Breekveldt-Postma et al. (Breekveldt-Postma et al., 2007) evaluated medication persistence 
among COPD patients in the first therapy year; new users of tiotropium, ipratropium, 
LABA and a fixed combination of LABA and ICS (LABA + ICS) were included in their 
study. The persistence was the highest, 37%, with tiotropium. The COPD patient’s drug-
taking behaviour was found to be significantly lower with other inhaled medications 
(ipratropium: 14%, LABA: 13%, LABA + ICS: 17%). Subgroup analysis of persistence data in 
patients with prior hospitalisation for COPD indicated that hospitalisation may have an 
enhancing effect on patient cooperation. The one-year persistence rates were increased by 2–
3 times in the first year after hospitalisation (tiotropium: 61%, ipratropium: 37%, LABA: 
41%, LABA + ICS: 33%). A similar study by Cramer et al. (Cramer et al., 2007) examined 
trends in patient persistence with inhaled COPD medication. They monitored the refill data 
of ipratropium, ipratropium + salbutamol, formoterol, formoterol + budesonide, salmeterol, 
salmeterol + fluticason and tiotropium in a cohort of 31,368 COPD patients. The one-year 
persistence was considerably higher with tiotropium (53%) compared with other treatments 
(7%–30%). The significant differences in levels of adherence and persistence between 
inhaled medications could be partially the result of dosing frequency. 
All of the aforementioned studies examined primary adherence, which is based on 
prescription refill rates. These results represent the maximum possible level of patient 
cooperation because refill adherence cannot confirm ingestion and does not provide any 
information on the frequency of medication use. Studies evaluating secondary adherence 
can provide data about medication use that is more reliable.  
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The Lung Health Study (Rand et al., 1995) was a double-blind, multicentre, randomised, 
controlled trial on smoking intervention and bronchodilator therapy (ipratropium or 
placebo) as early interventions of COPD. Satisfactory adherence was reported by 70% of the 
participants at the first 4-month follow-up visit, but this rate declined to 60% over the next 
18 months. The overall adherence estimated by canister weighing was 72% in the first year 
and 70% in the second year. Nevertheless, in the first year, only 48% of the participants were 
classified as adherent with both methods. In an ancillary study within the Lung Health 
Study, medication adherence rates measured by both self-report and canister weighing were 
compared with data from electronic medication monitoring (Rand et al., 1992). This study 
found that self-reporting and canister weighing significantly overestimate adherence: only 
15% of the participants used their inhaler 2.5 or more times per day (when three puffs per 
day were prescribed). In addition, 14% of the patients seemed to be “dumping” medication 
prior to the clinic visit by removing most of the medication at one time (i.e., actuating 
inhaler more than 100 times in a 3-h interval) to hide non-adherence. The level of adherence 
with the prescribed medication regimen was best immediately following each follow-up 
visit and declined during the interval between follow-up visits. The adherence after each 
visit was lower for each successive follow-up. These trends could be observed only with 
electronic medication monitors; self-reporting or weighing could not detect these changes 
(Simmons et al., 1996). 
Studies also suggest that while the underuse of medication seems to be one of the largest 
problems in the management of COPD, overuse is also common. Symptom-relieving drugs, 
such as short-acting β2 agonists (SABA), are more often overused than maintenance 
therapies (Dekker et al., 1993). Krigsman et al. (Krigsman et al., 2007a) evaluated the 
primary adherence in patients with asthma and COPD. The obtained results indicated that 
53% of the patients underused and 18% overused their prescribed medication regimens. In 
another study by Krigsman et al. (Krigsman et al., 2007b), it was found that 59% of COPD 
patients had an undersupply and 12% had an oversupply of ICS medication. 
Eighty-four percent of COPD patients have one or more co-morbidity (Yeo et al., 2006). For 
this reason, a question arises about whether the level of a patient’s adherence is the same with 
therapies for different chronic diseases. Krigsman et al. (Krigsman et al., 2007c) investigated 
refill adherence in patients who suffered from diabetes and COPD. Participants showed higher 
adherence for their diabetes drugs (68%) than their COPD medications (42%).  
Long-term oxygen therapy (LTOT) plays an important role in the management of COPD 
(Würtemberger & Hütter, 2000). The daily duration of oxygen administration is crucial in 
the effectiveness of LTOT. Pepin et al. (Pepin et al., 1996) found that only 45% of the COPD 
patients who were prescribed oxygen therapy for an average of 16 hours per day (16±3 h/d) 
used oxygen for 15 hours or more per day. Another study reported that 23% of the patients 
who had been prescribed LTOT refused to use liquid oxygen away from home and that 12% 
underused their oxygen (Würtemberger & Hütter, 2000). 
Immunisation with both the influenza and pneumococcal vaccines may produce a number 
of acute exacerbations, hospitalisation and COPD mortality (Nichol et al., 1999; Varkey et al., 
2009). However, the vaccination rates in patients with chronic lung diseases are low (Nichol 
et al., 1999; Tuppin et al., 2011), and the willingness to vaccinate differs by age group. The 
influenza vaccination status is significantly higher in patients aged 65 years or older (86.2%) 
than in the younger population (65.7%) (Mehuys et al., 2010). 
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3.2 Adherence to non-drug therapy 
Adherence to non-drug therapies, such as respiratory rehabilitation, exercise programs, 
healthy lifestyle or smoking cessation, is crucial in the management of COPD. 
Approximately 60% of the patients refuse to take part in rehabilitation programs, and out of 
those who join, 30% fail to complete the program (Nici et al., 2006). The most important 
barriers to rehabilitation adherence include exacerbations and progression of COPD 
(Bourbeau et al., 2007; Brooks et al., 2002). The literature in this field is quite weak; there is a 
clear need for further research to find out more about the suboptimal adherence to non-drug 
therapies in patients with COPD. 
4. Factors associated with adherence in patients with COPD 
Non-adherence in patients with COPD is a multidimensional phenomenon. The factors 
include the characteristics of the patient, the disease, the therapies and the health-care 
provider–patient relationship; many of these are potentially modifiable (Baiardini et al., 
2009; Restrepo et al., 2008; WHO, 2003) (Table 4). 
 
COPD 
 Progressive nature of the disease Ņ* 
 Poor prognosis Ņ 
 Lack of clinical symptoms Ņ 
 Disease severity ― 
 Lung function ― 
Treatment 
 Polypharmacy Ņ 
 Higher dosing frequency Ņ 
 Higher medication cost Ņ 
 Side effects Ņ 
 Oral administration Ń  
Patient 
 Gender - 
 Demographic factors: old age Ń 
 Improved quality of life Ņ 
 Social support Ń 
 Psychiatric co-morbidities Ņ 
Health-care provider–patient relationship 
 Higher quality of communication Ń 
 Type of caregiver: specialist Ń 
 Closer follow-up Ń 
 Hospitalisation Ń 
*Influence on adherence: decrease (Ņ), improve (Ń), no effect (―) 
Table 4. Factors associated with adherence in patients with COPD 
4.1 Factors related to the characteristics of COPD 
COPD is a progressive chronic disease. Adequate cooperation with COPD therapy can 
improve the patient’s quality of life and reduce the frequency of exacerbations but cannot 
fully control the disease symptoms. A progressive decline in lung function is often 
interpreted by patients as the medication not helping, so they stop following the 
recommendations (Chambers et al., 1999). In contrast, a lack of clinical symptoms could also 
be a reason for suboptimal adherence (DiMatteo, 2004). As implied above, the negative 
impact of COPD severity or lung function on a patient’s adherence is not obvious. Prior 
studies have shown that disease severity or the post-bronchodilator forced expiratory 
volume in one second (FEV1) percentage may be either not (Agh et al., 2011) or negatively 
(Turner et al., 1995) related to adherence. The pathologic characteristics of COPD influence 
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adherence to non-drug therapy as well; a poor COPD prognosis has been identified as one 
of the most demotivating factors to quit smoking (George et al., 2006b). 
4.2 Factors related to the characteristics of the patient 
Most prior studies have found that gender does not influence the level of patient 
cooperation (Agh et al., 2011; Apter et al., 1998; Corden et al., 1997; Turner et al., 1995). 
Adherence differences between men and women reported in the literature may be caused by 
psychological factors (Laforest et al., 2010). The prevalence of anxiety and depression are 
higher in women with COPD, and these psychiatric comorbidities have been independently 
linked with non-adherence ( Bosley et al., 1995; DiMatteo et al., 2000). 
In general, drug-taking behaviour is related to age; older patients seem to be more adherent. 
Patients of advanced age are more likely to adhere to therapy that requires adjustments in 
daily life (Agh et al., 2011). However, memory loss and cognitive impairment, which are 
associated with both age and COPD duration, may adversely affect adherence (Incalzi et al., 
1997). 
Social support can also influence patient adherence. Stable family life has been found to 
improve adherence to medication regimens (Tashkin, 1995; Turner et al., 1995). Furthermore, 
the study by George et al. (George et al., 2006b) indicates that patients with a good relationship 
with family and friends may live longer and may quit smoking with a higher success rate. 
Better quality of life has been considered a trigger for non-adherence (Agh et al., 2011). 
Decision-making regarding patient adherence is a personal trade-off between the efficacy of 
the therapy and the negative effects that it generates. Adherence to COPD therapy can 
reduce the clinical symptoms and improve the patient’s quality of life. However, COPD 
treatment regimens require adjustments in daily life, such as smoking cessation and exercise 
programs, and can cause side effects as well. Therefore, the interruption of drug therapy can 
temporarily also increases the patient’s quality of life. Therapy in newly diagnosed COPD 
patients may significantly improve quality of life; however, the change in quality of life may 
be much smaller in patients treated previously for longer durations (Soumerai et al., 1991). 
From the patient’s perspective, the benefits from the increase in the quality of life during the 
complication-free period can outweigh the effects of the worsening disease symptoms (Agh 
et al., 2011).  
4.3 Factors related to the characteristics of the therapy 
The number of medications and the dosing frequency have been linked with adherence. 
According to our evaluations, the dosing frequency of respiratory drugs is one of the most 
important factors affecting non-adherence in patients with COPD (Agh et al., 2011; WHO, 
2003). As a partial result of the daily drug doses, a significant difference has been shown in 
the adherence rates between the different respiratory drug classes (Apter et al., 1998; 
Breekveldt-Postma et al., 2007; Laforest et al., 2010). Tiotropium, a once-daily inhaled drug, 
may enhance adherence compared with other inhaled respiratory medications that are 
dosed more times daily. We also found that polypharmacy is another common cause of poor 
adherence (Agh et al., 2011); complicated treatment regimens may frustrate the patients, 
which may lead to non-adherence (van der Palen et al., 1999). 
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Patient cooperation is better with oral medication than with inhaled drugs (James et al., 
1985; Tashkin et al., 1991). Adherence with inhaled drugs may be compromised by 
inadequate inhaler technique (Garcia-Aymerich et al., 2000; Shrestha et al., 1996). 
Furthermore, better adherence with oral theophylline can also be due to the simplicity of the 
dosing regimens (Kelloway et al., 1995).  
Other factors, such as adverse effects and medication costs, are also important. Medication 
cost is one of the greatest barriers to achieving adequate adherence (Cramer et al., 2007, Jung 
et al., 2009). Side effects or concerns about side effects from medications can reduce 
adherence as well (Dolce et al., 1991; Rand et al., 1995). For example, patients with COPD 
often confuse the side effects of ICS with those of anabolic steroids, which may decrease 
their cooperation willingness (Boulet, 1998).  
4.4 Factors related to the characteristics of the health-care provider–patient 
relationship 
Effective COPD management requires a good relationship between health-care providers 
and the patients. Quality of communication is related to adherence. Adherent patients 
report better overall communication with their providers (Blais et al., 2004). Education 
during the consultation and providing more information about the therapy may improve 
adherence (Raynor, 1992), as it reduces the risk of forgetting the providers’ 
recommendations and the likelihood of misunderstandings between providers and patients. 
Previous studies suggest that immediately after the consultation, patients recall less than 
50% of the information conveyed by their provider (DiMatteo, 1991).  
The type of caregiver also influences adherence. Medication adherence may increase if the 
prescribing physician is a specialist instead of a general practitioner (Lau et al., 1996). 
Furthermore, periodic visits, closer follow-up and hospitalisation may also have increasing 
effects on patient cooperation (Breekveldt-Postma et al., 2007).  
5. Adherence enhancing interventions 
Strategies for improving patient adherence have to be formulated based on factors related to 
adherence. Seventy-six adherence interventions were evaluated in the systematic review by 
Petrilla and Benner (Petrilla & Benner, 2003).  
They identified the following main categories of adherence-enhancing interventions: 
- coordination of healthcare: improved linkages between primary care physicians, 
clinicians and other health professionals; 
- live consultation and education; 
- changes to the therapy dose, dosage and packaging to enhance the drug-taking 
convenience; 
- patient education materials; 
- disease management programs by clinicians; 
- reminders: medication refill reminders delivered by mail or telephone; 
- self-monitoring; 
- social support programs; 
- and combinations of these interventions. 
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Successful adherence-enhancing programs include simplified treatment regimens, 
facilitation of the physician–patient relationship and patient education methods (Petrilla & 
Benner, 2003). 
While many studies have evaluated strategies to enhance adherence, few of these have 
focused on COPD. Strategies for improving adherence in COPD include simplifying 
treatment regimens, improving communication between providers and patients, disease 
education, optimising inhaler technique, reinforcement and self-management (self-
monitoring of symptoms and medication use). 
It may be important to prescribe drugs with a fixed combination and/or a low dosing 
frequency to enhance adherence to COPD medication. Furthermore, the recommended 
treatment should fit into the patient’s limitations and lifestyle. Because many COPD patients 
are elderly, with the dual risk of cognitive impairment and complex medication regimens, 
the use of dosing aids and adherence devices, such as medication lists, dosette boxes and 
timers, should be promoted.  
Health-care providers must help their patients understand the progressive nature of COPD 
and the goals of the comprehensive treatment regimens. Physicians should actively involve 
patients in decisions regarding their therapy and give strong weight to their personal 
preferences and concerns. Periodic monitoring, understanding the patient’s beliefs and 
positive reinforcement could also enhance adherence to therapy (Dunbar et al., 1979).  
6. Conclusion 
Suboptimal adherence to medication regimens and to other non-drug therapies are both 
major problems in the management of COPD. Poor adherence poses a significant health and 
economic burden in patients with COPD. Non-adherence seems to be influenced by many 
individual reasons, such as factors associated with the characteristics of the disease, the 
patient, the therapy and the physician-patient relationship. Among other things, simplified 
treatment regimens, adequate patient education methods and better communication 
between caregivers and patients have been found to be critical for overcoming the barriers 
of poor adherence. However, further research is needed to identify factors related to patient 
cooperation to develop more effective strategies that can improve adherence.  
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